Johnson & Johnson vs Teradyne, Inc. — how do they compare? Johnson & Johnson trades at $259.22 (market cap $618.09B), while Teradyne, Inc. trades at $404.21 (market cap $62.34B). The key difference: Johnson & Johnson is far larger — about 9.9× Teradyne, Inc.'s market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Teradyne, Inc. for 37 Days on average.
| JNJ | TER | |
|---|---|---|
Market Cap | $618.09B | $62.34B |
Volume | 6,050,983 | 3,368,404 |
Sector | Health | Technology |
52-Week High | $278.43 | $483.84 |
52-Week Low | $186.00 | $132.05 |
Typical Hold Time | 129 Days | 37 Days |
Enterprise Value | $646.37B | $62.08B |
Dividend Yield | 2.09% | 0.13% |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
Teradyne (TER) trades at $411.78, down 4.31% today but maintains strong technical momentum with bullish moving averages and support at $407. The company demonstrates robust fundamentals with three consecutive earnings beats, 25.77% net margins, and 36.66% ROE. Recent product launches including Magnum E2 and Iris 100 position TER to capitalize on AI-driven semiconductor testing demand. Revenue is projected to grow from $3.19B in 2025 to $4.5B in 2026 according to company guidance.
TER presents a compelling growth opportunity with dominant positioning in semiconductor testing equipment and strong AI tailwinds. However, elevated valuation multiples (P/E 54.77, P/S 14.11) require continued execution. Key risks include semiconductor cycle volatility and competitive pressure from KLAC and COHU. Analyst consensus remains bullish with $461.50 price target representing 12% upside from current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →